Skip to main content

Matexcel

MaterialsBohemia, New York, USAFounded 2018· One of 961 Materials companies tracked by AMPulse

Supplies advanced materials including polymers, nanoparticles, metals, and ceramics for additive manufacturing and research, enabling custom synthesis and characterization services.

CEO / Founder
Rob Verheul
Team Size
51-200
Stage
Active
Total Funding
$461.1K

Technology & Products

Key Products

Polymers; Nanoparticles; Metal powders (e.g., titanium alloys, nickel-based alloys); Ceramics; Graphene derivatives; Hydrogels; Custom synthesis services; Material characterization and testing

Technological Advantage

Proprietary atomization techniques (plasma rotating electrode process) yield high-quality metal powders with superior flowability and density, verified by industry publications; expertise in polymer science supports tailored material development.

Differentiation

Value Proposition

Provides a one-stop solution for specialized materials with high purity and tailored properties, reducing material sourcing time and ensuring quality for AM applications.

How They Differentiate

Focuses on a broad material range (polymers, metals, ceramics, nanoparticles) with custom synthesis and characterization services, unlike larger players like Carpenter Technologies that may specialize in specific metals; offers niche expertise in polymer and nanoparticle materials for AM research.

Market & Competition

Target Customers

Academic institutions, industrial R&D labs, pharmaceutical and biotechnology companies

Industry Verticals

Additive Manufacturing; Biotechnology; Pharmaceutical; Aerospace; Automotive; Environmental Science

Competitors

AEM Product; LSN Diffusion; CVMR; Polymer Ventures

Growth & Milestones

Growth Metrics

Revenue reported as $5.9 million in 2024.

Major Milestones

Expanded offerings to include wide selection of metal powders using hybrid atomization technology; Extended product analysis services for AM optimization

Notable Customers

National Institutes of Health; Longevity Biotech; Peroxitech Therapeutics